Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in patients with metastatic or recurrent clear cell renal carcinoma (RCC). The primary objective was not achieved in the study.

Idera Pharmaceuticals (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLRs), today announced the formation of an Autoimmune Disease Scientific Advisory Board.

Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that, under its collaboration agreement with Merck & Co., Inc., a preclinical milestone was achieved with one of its novel Toll-Like Receptor (TLR) 9 agonists used as an adjuvant in cancer vaccines.